Advancing novel nanoparticle-based treatments for ocular disease


Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.


Year Invested: 2009
Location: Waltham, Mass.
Visit: www.kalarx.com

Recent News

January 6, 2017
Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference

April 13, 2016
Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing

May 14, 2015
Kala Pharmaceuticals Appoints Mark Iwicki as Executive Chairman

Read More News

Associated Team Members

Robert Tepper, M.D.
Partner